News, infos and good to know WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: Lirumlarum1

https://ir.immunitybio.com/news-releases/news-release-details/anktivar-bcg-demonstrates-96-survival-bladder-cancer-three-years?field_nir_news_date_value[min]=

ImmunityBio erhält von der Europäischen Arzneimittel-Agentur eine Empfehlung zur bedingten Marktzulassung für ANKTIVA® mit BCG zur Behandlung von nicht-muskelinvasivem Blasenkrebs (Carcinoma in situ) – eine Premiere in Europa. https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-receives-conditional-marketing-authorization

https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-immunitybio-ibrx-blurbs

https://www.prnewswire.co.uk/news-releases/rhabdomyosarcoma-market-is-expected-to-rise-throughout-forecast-period-20252034-with-promising-drug-candidates-in-pipeline--delveinsight-302627334.html

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy https://ir.immunitybio.com/news-releases/news-release-details/immunitybios-anktivar-reverses-lymphopenia-and-extends-overall?field_nir_news_date_value[min]=

https://x.com/DrPatSoonShiong/status/1961957310722703767

https://ir.immunitybio.com/news-releases/news-release-details/initial-data-shows-100-disease-control-5-out-5-patients?field_nir_news_date_value[min]=